Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 25.4 Thousand CAD | 769.96% |
| 2022 | -3792.00 CAD | 24.13% |
| 2021 | -4998.00 CAD | -389.07% |
| 2020 | 1729.00 CAD | 6.33% |
| 2019 | 1626.00 CAD | 118.8% |
| 2018 | -8647.00 CAD | -186.7% |
| 2017 | -3016.00 CAD | -412.93% |
| 2016 | -588.00 CAD | 8.27% |
| 2015 | -641.00 CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 488.00 CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -578.00 CAD | 98.01% |
| 2024 Q2 | -577.00 CAD | 0.17% |
| 2023 Q4 | -29.08 Thousand CAD | -205.33% |
| 2023 Q3 | 27.61 Thousand CAD | 3856.46% |
| 2023 FY | 25.4 Thousand CAD | 769.96% |
| 2023 Q1 | -735.00 CAD | 22.47% |
| 2023 Q2 | -735.00 CAD | 0.0% |
| 2022 Q2 | -948.00 CAD | 0.0% |
| 2022 FY | -3792.00 CAD | 24.13% |
| 2022 Q4 | -948.00 CAD | 0.0% |
| 2022 Q3 | -948.00 CAD | 0.0% |
| 2022 Q1 | -948.00 CAD | 24.16% |
| 2021 Q2 | -2043.00 CAD | -348.03% |
| 2021 Q1 | -456.00 CAD | -936.36% |
| 2021 Q4 | -1250.00 CAD | -0.08% |
| 2021 FY | -4998.00 CAD | -389.07% |
| 2021 Q3 | -1249.00 CAD | 38.86% |
| 2020 Q1 | 1204.00 CAD | -25.95% |
| 2020 Q4 | -44.00 CAD | -269.23% |
| 2020 Q2 | 543.00 CAD | -54.9% |
| 2020 Q3 | 26.00 CAD | -95.21% |
| 2020 FY | 1729.00 CAD | 6.33% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q4 | 1626.00 CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 FY | 1626.00 CAD | 118.8% |
| 2019 Q1 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 FY | -8647.00 CAD | -186.7% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 FY | -3016.00 CAD | -412.93% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 100.0% |
| 2016 Q4 | -724.73 Thousand CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | -588.00 CAD | 8.27% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 FY | -641.00 CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2007 Q2 | 5581.00 CAD | 55.07% |
| 2007 Q3 | - CAD | -100.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q1 | 3599.00 CAD | 0.0% |
| 2006 FY | - CAD | -100.0% |
| 2006 Q4 | - CAD | -100.0% |
| 2006 Q3 | 295.00 CAD | 100.68% |
| 2006 Q2 | 147.00 CAD | -0.68% |
| 2006 Q1 | 148.00 CAD | 0.0% |
| 2005 FY | 488.00 CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.831% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -718.988% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.741% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.783% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.979% |
| Mesoblast Limited | -35.16 Million USD | 100.072% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 174.392% |
| Genus plc | 178.7 Million USD | 99.986% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 93.806% |
| Marizyme, Inc. | 457.7 Thousand USD | 94.449% |
| ContraFect Corporation | -154 Thousand USD | 116.497% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 330.955% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 150.81% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 66.904% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 61.348% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 106.556% |
| MultiCell Technologies, Inc. | 49.32 USD | -51410.543% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.937% |
| EV Biologics, Inc. | 48.9 Thousand USD | 48.047% |
| Q BioMed Inc. | -8988.00 USD | 382.655% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.91% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 264.711% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.988% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 63.707% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 120.447% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 59.173% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 613.025% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1141.615% |
| IMV Inc. | -962.29 Thousand USD | 102.64% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 81.918% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 126.052% |
| GB Sciences, Inc. | -624.00 USD | 4171.314% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 129.531% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Halberd Corporation | -208.00 USD | 12313.942% |
| Enzolytics Inc. | 30.7 Thousand USD | 17.269% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 98.128% |
| SYBLEU INC | 11.69 Thousand USD | -117.211% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 94.734% |
| argenx SE | 1.1 Billion USD | 99.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.098% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 95.885% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.994% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 386.868% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.943% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 102.225% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 97.429% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.736% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 130.299% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.835% |
| ONE Bio Corp. | 20.12 Million USD | 99.874% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 314.66% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 152.643% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 85.611% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 85.611% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 104.938% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 104.032% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 187.603% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 94.355% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 107.951% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.449% |
| Bioxytran, Inc. | -8285.00 USD | 406.639% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 106.811% |
| Neutra Corp. | 14.33 Thousand USD | -77.224% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 130.982% |
| PureTech Health plc | -1.6 Million USD | 101.585% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 102.537% |
| IXICO plc | 3.27 Million USD | 99.223% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 103.661% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 101.418% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | -41.139% |